Ro vs Hims for GLP-1 Weight Loss: Which Is Better in 2026?
Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.
Published provider headline prices with starting and recurring terms preserved.
Affiliate links, we earn a commission at no extra cost to you. Commercial placement; see the full price-sorted comparison on our rankings page.
Summarize this article with
Ro is the better fit if you want insurance support, while Hims is a cash-pay route with a broad current brand menu. Their lowest listed cash path is a tie: $149 Wegovy pill medication plus a required $39 first-month/$149 ongoing membership, or $188 initially and $298/mo thereafter. Both now list branded Wegovy after Hims and Novo Nordisk reached a new agreement in March 2026. Ro accepts insurance; Hims does not. Exact product, dose, coverage, and checkout line items can change the total. This comparison was reconciled to the provider records on August 14, 2026.
Comparing your options?
See every verified GLP-1 program ranked side by side on cost, safety, and care quality. The cheapest we track right now is $69/mo.
Compare all 54 GLP-1 providers →The Quick Verdict
Is Ro or Hims Cheaper for GLP-1?
Ro can be cheaper with qualifying commercial insurance; the lowest listed cash path is a tie. Both require a Weight Loss Membership at $39 in month one and $149/mo ongoing. Each lists the Wegovy pill medication from $149, making that path $188 initially and $298/mo thereafter. At Ro, eligible coverage and a manufacturer savings card may lower the medication copay; Hims takes no insurance.
| Ro | Hims | |
|---|---|---|
| Membership (1st month) | $39 | $39 |
| Membership (ongoing) | $149/mo | $149/mo |
| Wegovy pill (medication only) | $149-299/mo | From $149 |
| Wegovy pen (medication only) | $199 intro / $349 ongoing | From $199 |
| Wegovy pen (insurance) | Yes, as low as $25/mo | Not accepted |
| Zepbound (medication only) | $299 at 2.5mg; $399 at 5mg; $449 at 7.5mg+ with refill conditions | From $299; exact dose varies |
| Foundayo (medication only) | $149-$349 (dose/refill ladder) | $149-$349 (dose/refill ladder) |
| Compounded GLP-1 for new retail signup | Not listed; brand-name menu | Not listed; brand-name menu |
The biggest pricing difference: Ro accepts insurance. If your commercial insurance covers Wegovy, Ro's insurance concierge handles the prior authorization process for you. With a manufacturer savings card, your cost could drop to $25/month. Hims is strictly cash-pay, no insurance accepted, though FSA/HSA cards work.
For uninsured patients, the lowest pricing is a tie: each lists the Wegovy pill from $149 plus $39 membership in month one and $149/mo thereafter, or $188 initially and $298/mo ongoing. Higher-dose pills, pens, Zepbound, and other products can cost more.
Join the list for the GLP-1 Letter.
We re-verify every price on this site against the provider's own live page and check every program against the FDA warning letter database. Join the list and you will hear from us when that work turns up something worth an email. No promised schedule until we are actually keeping one. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
Which GLP-1s Do Ro and Hims Offer?
Both platforms expanded their medication offerings significantly in early 2026:
- •Ro lists Wegovy pill and pen, Ozempic, Mounjaro, Zepbound, and Foundayo on its current brand-name menu
- •Hims lists Wegovy pill and pen, Ozempic pill and pen, Foundayo, and Zepbound for new retail signups
- •Both list Zepbound medication from $299 and Foundayo from $149; dose/refill ladders and the required membership change the total
Ro launched the Wegovy pill on January 5, 2026, among the first telehealth platforms to offer it. Ro positions itself as a dedicated weight management platform, while Hims is a broader men's health platform that added GLP-1s to their existing hair loss, ED, and skincare offerings.
The Hims + Novo Nordisk Saga (Important Context)
The Hims-Novo relationship is a dramatic story that matters for understanding what you're getting today:
- •April 2025: Hims and Novo Nordisk announced a partnership to sell branded Wegovy on Hims at $599/month
- •June 2025: Novo terminated the deal after ~1 month, accusing Hims of continuing to sell compounded semaglutide made with unauthorized ingredients. Hims stock dropped 30%.
- •February 2026: Hims launched a $49/month compounded Wegovy pill copy. Novo immediately sued for patent infringement.
- •March 9, 2026: New deal reached. Novo dropped the lawsuit, and Hims moved new retail GLP-1 signups to a brand-name menu. Hims & Hers' Q2 2026 filing says the parent still provides access to compounded GLP-1s on a limited scale, so that corporate disclosure should not be read as a current compounded option for every new Hims patient.
Editor's Top Pick
Embody
from $69/mo · 7.3/10 · Compounded
Online weight-loss program that ships compounded GLP-1 medication to your door. Modern Metabolic Medicine, Inc. runs the storefront and OpenLoop Health supplies the clinical network on the current site. Embody now advertises compounded semaglutide from $79 and GLP-1 + GIP from $129; its FAQ says the chosen rate holds within a selected 4-, 12-, 24- or 52-week plan. Its standout is oral tirzepatide gum for people who do not want injections.
Clinical Support
| Feature | Ro | Hims |
|---|---|---|
| Consultation | Free async, 24hr provider review | Online assessment |
| Ongoing support | Monthly check-ins, unlimited messaging | 24/7 provider access, quarterly reviews |
| Health coaching | Included | Not included |
| Nutrition counseling | Included | Not included |
| Exercise planning | Included | Not included |
| Lab work | Metabolic labs may be required | Not required |
| Insurance concierge | Yes, handles prior auth | N/A (no insurance) |
Ro's clinical model is more comprehensive, it's a dedicated weight management program with health coaching, nutrition, and exercise support built in, a focus they've heavily marketed since their Super Bowl 2026 campaign. Hims offers provider access and check-ins but positions the medication as the primary intervention. If you want a hands-on program that goes beyond the prescription, Ro delivers more value. If you want straightforward medication access without extras, Hims is simpler.
Not sure which GLP-1 program is right for you?
Take the 60-second quiz, we'll match you against 54 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizUser Reviews
Ro has a 3.9/5 rating on Trustpilot across 5,086 reviews in our August 3, 2026 check. Common positives include convenience and provider communication; recurring negatives include customer service, delivery, and confusion about the $149 ongoing membership being separate from medication cost.
Hims had a 3.0/5 Trustpilot rating across 8,286 reviews in our May 2026 check. Those reviews span all Hims products rather than isolating weight loss. The 1-star pool was 28%, with subscription handling, unexpected charges, and support responsiveness among the recurring themes.
Who Should Choose Ro?
- •You have commercial insurance that might cover Wegovy, Ro handles prior authorization for you
- •You want comprehensive clinical support (coaching, nutrition, exercise planning)
- •You want access to Zepbound or the new Foundayo pill alongside Wegovy
- •You prefer a platform focused entirely on weight management
Who Should Choose Hims?
- •You're paying cash and can budget the $149 medication floor plus $39 first-month/$149 ongoing membership
- •You want a simple process, no insurance paperwork, no lab requirements
- •You already use Hims for other health products and want one platform
- •You want branded Wegovy pill or pen without comprehensive program extras
Our Ranking
In our provider rankings, Hims scores 7.9/10 and Ro scores 7.2/10, so Hims places higher under the published methodology. Both now list Zepbound and Foundayo, and their lowest $149 medication path carries the same required membership, so those points do not explain the score gap. Ro's concrete advantage is insurance billing; Hims has the higher current methodology score but the weaker Trustpilot signal in our stored checks. Neither score certifies an individual prescription, clinician, pharmacy, or outcome.
Not sure which is right for you? Take our match quiz to get personalized recommendations based on your budget, insurance status, and preferences, or use the cost calculator to estimate what you'd actually pay.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Done comparing? Our Top Pick is Embody
Our featured pick, scored 7.3/10 by our methodology, is listed at from $69/mo. Not sure it's the one for you? The 60-second quiz matches you to your budget and medication.
Featured affiliate pick, we may earn a commission · scores set by our methodology, not payment
Compare every GLP-1 program in one place
See all 54 verified providers ranked side by side on price, medication, and our independent score, or jump straight to the cheapest verified prices.
GLP-1 Storage and Travel: Heat, TSA Rules, and What to Do If It Was Left Out
News & PipelineCan GLP-1 Treatment Be Personalized? What New Penn and Mayo Studies Actually Show
News & PipelineRFK Jr. Proposes Medicare GLP-1 'Framework' (April 2026): Glucose Monitors First, Coverage Second
Keep exploring
- →Provider Rankings
- →Cheapest Providers
- →Take the Match Quiz
- →Weight Loss Predictor
- →Full Cost Guide
- →Cost Calculator
What the doctors say
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss, which in turn lowers the risk of many weight-related conditions. These treatments also improve patients' quality of life in a meaningful way, making this a genuine win, win.”
“It's the first time that we have seen this magnitude of weight loss compared to current medications on the market for obesity. It's 1.5 to 2.5 times more effective than currently available drugs.”
“Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before. The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.